Biomarkers in circulating vesicles for Ewing sarcoma
Official title: Feasibility Study for the Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas
Run by Istituto Ortopedico Rizzoli · NCT07685405 · Data updated 2026-11-12
Researchers will test blood samples from people with Ewing sarcoma to see if circulating biomarkers in extracellular vesicles can help validate new therapies.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Locations | 1 site (Bologna, BO) |
| Status | Recruiting |
| Started | April 15, 2026 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT07685405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Male and female patients of any age with a confirmed diagnosis of Ewing sarcoma, who can provide informed consent for the BIOVES study.
✕Probably not a fit
Non-cancer participants or those not meeting all inclusion criteria may not receive any direct benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects blood samples from patients with Ewing sarcoma to identify circulating biomarkers linked to extracellular vesicles. The goal is to support preclinical validation of innovative therapeutic approaches. The study design appears to involve multiple blood draws, with inclusion of both cancer patients and non-cancer controls to compare biomarker profiles. No interventional treatments are performed as part of the study; samples are used for exploratory analyses. The lead site is Istituto Ortopedico Rizzoli in Bologna, Italy.
Why it matters
Potential benefit: If successful, identifying circulating biomarkers could aid in monitoring disease and guiding future therapies for Ewing sarcoma.
How similar studies have gone: Biomarker studies in extracellular vesicles have shown promise in various cancers, but this approach in Ewing sarcoma is exploratory and not yet proven in this exact context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria for cancer patients * Male and female patients of any age diagnosed with Ewing sarcoma. * Signed, study-specific informed consent form for the BIOVES study (cancer patients) Inclusion criteria for non-cancer patients * Male and female patients of legal age without a cancer diagnosis. * Signed, study-specific informed consent form for the BIOVES study (non-cancer patients) Exclusion Criteria: Patients who do not meet all inclusion criteria \-
Where it's running
-
Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle
Bologna, Bo, Italy Recruiting
Study contacts
- Study coordinator: Katia Scotlandi, MSc
- Email: katia.scotlandi@ior.it
- Phone: 39 051 6366760
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sequential CD146- and HER2-targeted CAR T-cell therapy for advanced sarcoma
This treatment will test whether giving a patient's own CAR T cells that target CD146 and HER2, one after the other, can shrink tumors in children and adults with relapsed or refractory advanced sarcoma.
-
Testing a new drug combination for treating relapsed or refractory sarcomas in adolescents and young adults
This study is testing a new combination of drugs to see if it can help adolescents and young adults with tough-to-treat sarcomas feel better and improve their chances of recovery.
-
Using 3D printed models for planning bone tumor surgeries
This study is testing if using 3D printed models can help doctors plan surgeries for bone tumors better than just using imaging alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.